This opportunity is now closed.

Funded PhD Opportunity

Bioinformatics approach to identifying effective sensitising therapeutics for rheumatoid arthritis

Subject: Biomedical Sciences


Summary

Rheumatoid arthritis (RA) is a chronic destructive disease of joints, which affects ~ 25 million adults in the world. RA is a painful and disabling disease and presents significant healthcare burden to society. Connectivity mapping (Lamb et al 2006) is an advanced bioinformatics technique that establishes connections among different biological states via their gene expression profiles/signatures. An important application of connectivity mapping is the identification of small molecule compounds capable of inhibiting a disease state, or more generally, altering a disease state towards a more favourable condition, for example, enabling patients to be more responsive to an otherwise ineffective treatment. Our team has undertaken pioneering research in this area, by developing a robust framework for connectivity mapping, releasing tested tools for such high throughput tasks, and successfully applying the developed technologies to different disease areas including cancers and inflammatory diseases [Zhang & Gant 2008, 2009; McArt & Zhang2011; McArt et al 2013; Wen et al 2015, 2016; Ramsey et al 2013;Malcomson et al 2016, PNAS;Wen et al 2017].

In this project, we will apply the connectivity mapping principle to rheumatoid arthritis (RA). This project aims to develop an integrated Bioinformatics and Big Data approach to the identification of sensitising agents that can improve RA patients’ response to biological treatments, such as infliximab (IFX), tocilizumab (TCZ), or abatacept (ABT).  Successful identification of such effective sensitising agents can help to address important unmet clinical needs, and bring great benefits to patients and NHS. Although this project focuses on non-responsive rheumatoid arthritis as a target disease, the approach developed and tested is also readily applicable to other disease areas of stratified medicine.

The Aims of the research project are:  1) To identify suitable public data sets of RA patients with gene expression profiling data (eg, those deposited in public data repository GEO and/or ArrayExpress) and clinical data on their response to standard DMARDs and biological treatments (eg. IFX, TCZ, ABT). 2) Use the multi-omics data and clinical data available in the retrieved public data sets, to identify gene signatures that are characteristic of response to certain biological treatments for RA.  3) To process and analyse the drug-induced gene expression data to construct reference gene expression profiles for FDA-approved drugs and experimental compounds available through the LINCS database.  4) To establish the connections between the IFX-response gene signatures generated in Aim 2 and the reference drug profiles in Aim 3, to identify candidate chemical agents, particularly FDA approved drugs, which have the desirable effects on the specific IFX-response gene signatures and therefore be able to sensitise IFX-treatments and induce remission in otherwise non-responsive RA patients  5) To validate the predicted effects of candidate drugs on model systems of the disease.

This is an interdisciplinary bioinformatics and BigData  research project; it requires an individual with good computational skills and statistical knowledge.  A good understanding of basic biological processes and some experience with basic biological lab experiments would be desirable, but training on these aspects will be provided during the course of PhD study.


Essential criteria

  • Upper Second Class Honours (2:1) Degree or equivalent from a UK institution (or overseas award deemed to be equivalent via UK NARIC)

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.


Funding


Other information


The Doctoral College at Ulster University


Reviews

My experience has been great and the people that I have worked with have been amazing

Kieran O'Donnell - 3D printing of biological cells for tissue engineering applications

Watch Video  

Completing the MRes provided me with a lot of different skills, particularly in research methods and lab skills.

Michelle Clements Clements - MRes - Life and Health Sciences

Watch Video  

Throughout my PhD I’ve been provided with continuous support and guidance by my supervisors and the staff at the University.I’ve also received many opportunities to further enhance my professional development in the form of teaching experience and presenting my work at conferences which will aid in my pursuit of a career in academia or industry.

William Crowe


Key dates

Submission deadline
Monday 19 February 2018

Interview Date
6, 7 and 8 March 2018


Contact supervisor

 

Telephone

Email


Other supervisors


Applying

Apply Online

Related Funded Opportunities in: Biomedical Sciences ,

The production of rhamnolipid biosurfactant by Pseudomonas aeruginosa growing in biofilms.

Closing date:
Sunday 1 September 2019
Subject:
Biomedical Sciences

 View Details

The regulation of rhamnolipid biosynthesis in Burkholderia thailandensis.

Closing date:
Sunday 1 September 2019
Subject:
Biomedical Sciences

 View Details

Diabetes

Subject:
Biomedical Sciences

 View Details

Genomic Medicine

Subject:
Biomedical Sciences

 View Details

Novel amphibian skin peptide-analogues for the treatment of type-2 diabetes

Closing date:
Wednesday 18 September 2019
Subject:
Biomedical Sciences

 View Details

Using the Eye to Predict risk for Cardiovascular disease- The Living Lab

Closing date:
Friday 27 September 2019
Subject:
Biomedical Sciences|Engineering

 View Details

The design and analysis of a novel photo-activated antimicrobial system

Closing date:
Sunday 1 September 2019
Subject:
Biomedical Sciences

 View Details

Stratified Medicine

Subject:
Biomedical Sciences

 View Details

Optometry and Vision Science

Subject:
Biomedical Sciences

 View Details

MRes in Biomedical Sciences

Subject:
Biomedical Sciences

 View Details

Molecular Pathology of Glaucoma

Closing date:
Wednesday 1 January 2020
Subject:
Biomedical Sciences

 View Details